Contrave

Short answer: yes — if you stop a GLP‑1 (semaglutide, tirzepatide, etc.) most people will regain at least some — often much — of the weight they lost unless they replace the drug’s effect with strong, sustained lifestyle and/or other medical interventions. Stopping doesn’t permanently “reset” appetite or metabolism for most people; the drug’s appetite‑suppressing and metabolic effects wear off and hunger, food reward, and energy balance often revert. What typically happens after stopping Appetite and cravings usually increase. GLP‑1 drugs reduce hunger and food reward; when they’re stopped those signals typically return. Weight regain is common and can begin within weeks to months; many studies and clinical experience show substantial regain over 6–12 months if no other measures are taken. If you are taking the GLP‑1 for diabetes, stopping can raise blood glucose; you’ll need closer monitoring and possible adjustments of other diabetes medicines. Side effects that occurred while taking the drug (nausea, constipation) generally improve after stopping. If you plan pregnancy, GLP‑1s are usually stopped because fetal safety isn’t established. Why regain happens GLP‑1 drugs treat physiology (appetite, satiety, gastric emptying) but not always the behavioral, environmental, or biological drivers that led to weight gain in the first place. Metabolic adaptations to weight loss (lower resting energy expenditure, stronger hunger signals) persist and are unmasked when the drug is stopped. How to reduce or slow regain (practical steps) Don’t stop abruptly without a plan. Talk with your prescribing clinician first. If you have diabetes, glucose monitoring is essential. Work with a team: primary care or endocrinologist + registered dietitian (RD) experienced in weight management. RDs can teach meal plans, protein/fiber strategies, and appetite management. Nutrition & exercise: prioritize higher protein, fiber, and regular resistance training to preserve lean mass and resting metabolism. Aim for consistent meals and reduce liquid calories. Behavioral strategies: structured programs, cognitive behavioral therapy (CBT) for eating, and regular self‑monitoring (weight, food logs) help maintain loss. Consider pharmacologic maintenance: some people switch to or continue a lower‑dose GLP‑1 as maintenance or use another FDA‑approved obesity med (see options below). Discuss risks, benefits, and cost with your clinician. Regular follow‑up and early action if weight starts to creep back up (more intensive diet/physical activity or re‑starting meds) give the best chance to maintain loss. Medications and services you can discuss with your clinician GLP‑1s: Wegovy and Ozempic (semaglutide), Zepbound or Mounjaro (tirzepatide). These are effective for weight but most benefit is while you stay on them. Other FDA‑approved options for weight management: Saxenda (liraglutide), Qsymia (phentermine/topiramate), Contrave (bupropion/naltrexone), and orlistat (Xenical/Alli). These have different side effects and efficacy — your doctor can advise which might suit you. Behavioral programs: WW (Weight Watchers) or the CDC Diabetes Prevention Program (DPP) for structured lifestyle support. These provide regular coaching and accountability. Digital tools: Noom (behavioral/psychology focus), MyFitnessPal or Cronometer (tracking calories and protein). These help with self‑monitoring, which predicts better maintenance. Professional support: find a board‑certified obesity medicine specialist or endocrinologist, and a registered dietitian (look for “RD” or “RDN”). Many clinics offer multidisciplinary weight‑management programs. Questions to ask your clinician before stopping What will happen to my blood sugar/medications if I stop? Can we create a maintenance plan (diet, exercise, follow‑up schedule) before I stop? Are there alternative medications or a taper/transition strategy appropriate for me? What monitoring (weight, labs) should we do and how often? Bottom line Stopping a GLP‑1 commonly leads to increased appetite and weight regain unless you have a concrete, evidence‑based maintenance plan (behavioral program, diet/exercise, and/or alternative medication). Talk with your prescriber and a dietitian to create a personalized plan before you stop so you can maximize the chance of keeping your losses. If you want, tell me which medication you’re on and why you’re stopping (cost, side effects, pregnancy, etc.), and I can suggest a more specific transition plan and questions to take to your clinician.

Mentioned in position 7 of 13

I’m glad you asked — losing 30 pounds is a big goal and there are several medically safe paths beyond “diets” alone. Which option is best depends on your BMI, health conditions, prior attempts, insurance and how you want to lose the weight. Below is a concise, practical rundown of evidence-based options, the common brand names, why they’re used, and what to do next. 1) Comprehensive lifestyle + behavioral programs (first-line for everyone) What: Structured plans with a registered dietitian (RD), behavior change/CBT, exercise plan and regular follow-up. Brands/services: WW (WeightWatchers) — widely available behavioral program; Noom — app-based cognitive behavioral approach; local medical weight-management clinics that include RDs and exercise specialists. Why: Support, accountability and behavior change improve long-term success compared with “do-it-yourself” diets. 2) Prescription medications for chronic weight management For many people with BMI ≥30 or ≥27 with weight-related conditions (hypertension, diabetes, sleep apnea), these can produce significant, sustained loss. GLP‑1 and GIP/GLP‑1 agonists: Wegovy (semaglutide) — approved specifically for weight loss; strong average weight loss in trials. Zepbound (tirzepatide) — newer option that has produced very large average weight loss in studies. (Related: Ozempic/Mounjaro are diabetes brands for the same/related drugs; dosing and indications differ.) Other FDA-approved meds: Qsymia (phentermine/topiramate) — stimulant + anticonvulsant combination helpful for many. Contrave (bupropion/naltrexone) — affects reward pathways and appetite. Xenical (orlistat) / Alli (OTC orlistat) — reduces fat absorption. Plenity (Gelesis) — prescription oral device (hydrogel) for BMI 25–40 to promote fullness. Why: These medications work on appetite, satiety and metabolism and often produce more weight loss than lifestyle alone. Side effects and costs vary; discuss with a clinician. 3) Endoscopic (non-surgical) options Intragastric balloons: Orbera (and similar devices) — placed endoscopically, left in stomach months to reduce volume and increase fullness. Endoscopic sleeve gastroplasty (ESG): Uses an endoscopic suturing device (e.g., Apollo OverStitch) to reduce stomach size without open surgery. Why: Less invasive than surgery, moderate weight loss, option for people not ready for surgery. 4) Bariatric (metabolic) surgery — most effective long-term for large weight loss Common procedures: Sleeve gastrectomy — removes a portion of the stomach. Roux-en-Y gastric bypass — reduces stomach size and changes absorption. Why: Produces the largest, most durable weight loss and often improves or resolves diabetes and other conditions. Typically considered for BMI ≥40, or BMI ≥35 with comorbidities (guidelines sometimes allow lower BMI for serious metabolic disease). Seek surgeons at MBSAQIP-accredited centers (e.g., major academic centers or accredited weight-loss centers). 5) Supportive medical care and evaluation (important before choosing a path) Get a medical evaluation: screen for thyroid disease, sleep apnea, diabetes, medications that cause weight gain, mental health issues, and readiness to change. Find specialists: primary care, an ABOM-certified obesity medicine specialist (search at American Board of Obesity Medicine), bariatric surgeons (MBSAQIP-accredited). Ask about insurance coverage—many insurers cover bariatric surgery and sometimes meds or programs; coverage for GLP‑1s varies. 6) What to avoid / be cautious about Unregulated supplements, “detox” cleanses, fad diets without medical supervision — often unsafe or ineffective. Very-low-calorie diets should only be done under medical supervision. Be aware of side effects and long-term commitment (some meds require ongoing use to maintain weight loss). Practical next steps I can help with Calculate your BMI if you tell me your height and weight. Draft questions to bring to your primary care or to an obesity clinic (e.g., medication options, surgical candidacy, costs/coverage). Help locate ABOM-certified obesity specialists or MBSAQIP-accredited bariatric centers nearby. If you want, tell me your current height, weight and any major medical conditions or medications and I’ll tailor recommendations (and calculate BMI) and suggest the most likely options for you.

Mentioned in position 4 of 8

Short answer: Yes — many people regain at least some or most of the weight when they stop GLP‑1 drugs unless they keep up strong lifestyle changes or switch to another long‑term strategy. GLP‑1s are powerful tools for lowering appetite and caloric intake, and stopping them usually lets appetite and food intake rise again. What’s happening physiologically GLP‑1 receptor agonists (semaglutide, tirzepatide, liraglutide, etc.) reduce appetite, increase satiety, slow gastric emptying and change food reward signals. When the drug is stopped those effects fade, so hunger returns and it’s easier to eat more. In addition, weight loss causes reduction in resting metabolic rate and hormonal changes (leptin/ghrelin etc.) that favor weight regain — these changes can persist after stopping the drug. What the evidence shows Clinical trials and follow‑up studies have repeatedly found that people tend to regain weight after discontinuing GLP‑1 therapy unless other measures are kept in place. For example, participants who stopped semaglutide in the STEP trials regained much of the lost weight over months to a year after stopping. Some people who adopt durable behavior changes (intensive dietary plans, exercise, cognitive/behavioral programs) keep a meaningful portion of their loss, but that’s less common than continued medication plus lifestyle support. Practical options if you plan to stop Plan the stop with your prescriber — sudden discontinuation doesn’t typically cause dangerous withdrawal, but appetite and GI symptoms can change and a plan helps. Intensify behavioral supports before/after stopping: meet with a registered dietitian, use structured programs (e.g., Diabetes Prevention Program, WW/WeightWatchers, Noom, local medical weight‑loss programs), and increase physical activity. Consider alternative or adjunct medications if appropriate: examples include other GLP‑1 or incretin agents (Wegovy or Ozempic — semaglutide; Saxenda — liraglutide; Mounjaro or Zepbound — tirzepatide), or non‑GLP options such as Contrave (naltrexone‑bupropion), Qsymia (phentermine/topiramate), or orlistat (Xenical/Alli). Your clinician can advise what’s best for your medical situation and goals. For some people, long‑term medication (just like long‑term treatment for hypertension or diabetes) is the most reliable way to maintain weight loss. When to talk to your clinician If you’re thinking about stopping because of side effects, cost, pregnancy planning, surgery, or other reasons — discuss it with the prescriber first. They can help taper if needed, suggest alternatives, and put a weight‑maintenance plan in place. If you want, tell me which GLP‑1 you're taking (brand or generic) and why you’re stopping (side effects, cost, pregnancy, finished program), and I can give more specific next‑step suggestions.

Mentioned in position 4 of 7

Here are some solid options to consider: Medical/Clinical Options WeightWatchers (WW) - Combines structured eating with behavioral coaching; strong long-term track record Noom - App-based program focusing on psychology behind eating habits Found or Calibrate - Telehealth platforms that can prescribe GLP-1 medications like Wegovy or Ozempic (semaglutide), which have shown significant clinical results Prescription Medications Wegovy (semaglutide) - FDA-approved specifically for weight loss, many people lose 15-20%+ of body weight Qsymia or Contrave - Other prescription options worth discussing with your doctor Structured Programs Jenny Craig - Pre-portioned meals with coaching Optavia - Meal replacement coaching program with strong community support Surgical Options (for significant/persistent weight struggles) Consult a bariatric specialist about sleeve gastrectomy or gastric bypass if other methods haven't worked Fitness Support NASM-certified personal trainer combined with MyFitnessPal for tracking My Top Recommendation Talk to your primary care doctor first - they can refer you to a weight loss specialist and discuss whether GLP-1 medications are appropriate for you. This is the most evidence-based starting point. Would you like more detail on any of these options?

Mentioned in position 6 of 10

Short answer: usually no — compounded GLP‑1s are rarely the best first option. They can be cheaper or easier to get, but they carry real safety, quality and legal risks and lack the FDA-approved manufacturing and testing that Wegovy (semaglutide 2.4 mg) has. There are safer, often better paths to pursue first. What to consider and practical next steps 1) Appeal the denial first Ask your prescriber to submit a formal prior‑authorization appeal or peer‑to‑peer review with the insurer and to write a letter of medical necessity documenting your BMI, weight‑related conditions, prior therapies tried, and why Wegovy is clinically indicated. Denials are often reversed on appeal. If you want, I can help draft a short appeal/medical‑necessity paragraph you can give your clinician. 2) Check manufacturer and savings programs Novo Nordisk offers patient support and savings programs for Wegovy. If you have commercial insurance, co‑pay savings or patient support may reduce cost; for Medicare recipients, manufacturer coupons usually aren’t allowed, but patient assistance programs may still help. Contact Novo Nordisk Patient Support for details. 3) Consider alternative, FDA‑approved options (safer than compounding) Zepbound (tirzepatide, Eli Lilly) — FDA‑approved for chronic weight management; may be covered differently by insurers and is very effective for weight loss. Mounjaro (tirzepatide, Lilly) — approved for type 2 diabetes but commonly used off‑label for weight loss; discuss this with your clinician. Ozempic (semaglutide, Novo Nordisk) — approved for diabetes; some clinicians use it off‑label at higher doses for weight management. Saxenda (liraglutide, Novo Nordisk) — older daily injectable weight‑loss drug, FDA‑approved for obesity. These have established safety data and manufacturer quality controls; your prescriber can try switching or request coverage for one of these. 4) Clinical trials and programs Look for clinical trials of GLP‑1 or tirzepatide products (ClinicalTrials.gov) — some trials provide medication at no cost. 5) If you’re thinking about compounded GLP‑1s — major cautions Compounded GLP‑1s are not FDA‑approved products. Quality (potency, purity) and sterility can vary. There have been reports of contamination, incorrect dosing, and supply of unauthorized ingredients. Insurance typically won’t cover compounded versions. If you still consider compounding, only use a reputable, accredited compounding pharmacy (look for PCAB accreditation and documented sterility/potency testing). Ask the pharmacy for their certificate of analysis, sterility testing procedures, lot records, and how the active pharmaceutical ingredient is sourced. Be extremely cautious about mail‑order or overseas sources, and avoid “too good to be true” prices. 6) Other options to discuss with your clinician Intensified lifestyle program, referral to a registered dietitian or behavioral program. Bariatric surgery evaluation if you meet criteria. Older, non-GLP‑1 medicines for weight management (Contrave, Qsymia) if appropriate. Summary recommendation Don’t jump to compounded GLP‑1s as the first fix. First: appeal the denial, check Novo Nordisk’s support programs, and ask your clinician about covered FDA‑approved alternatives such as Zepbound, Mounjaro, Ozempic, or Saxenda. Reserve compounding only as a last‑resort after careful vetting of a PCAB‑accredited pharmacy and full informed discussion about risks. If you want, tell me: Your insurance type (commercial, Medicare, Medicaid), BMI and any weight‑related conditions, and whether your clinician has tried an appeal — and I can help draft an appeal letter or suggest the most promising alternative based on your situation.

Mentioned in position 6 of 7

Short answer: maybe — it depends less on how many pounds you want to lose and more on your BMI (body‑mass index) and whether you have weight‑related health problems. Key points FDA approvals: Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are FDA‑approved for chronic weight management in adults with: BMI ≥ 30 (obesity), or BMI ≥ 27 (overweight) plus at least one weight‑related comorbidity (type 2 diabetes, high blood pressure, high cholesterol, sleep apnea, etc.). That means someone who only wants to lose 20 lb can still qualify if their current BMI meets those thresholds (or if they have a qualifying comorbidity). Many clinicians also prescribe GLP‑1s off‑label (for example Ozempic — semaglutide dosed for diabetes) but insurance usually will not cover off‑label weight use, and some prescribers won’t do it. What you should do next Calculate your BMI (weight in kg / height in m^2) or tell me your height and current weight and I can calculate it for you. Tell your primary care doctor or see an obesity medicine specialist to review medical history and contraindications (personal/family history of medullary thyroid carcinoma or MEN2, pregnancy or planning pregnancy, history of pancreatitis, certain GI conditions). Expect insurers to require documentation of BMI, possibly evidence of prior lifestyle attempts, and prior authorization for these drugs. Safety and alternatives Common side effects: nausea, vomiting, constipation, gallbladder issues; rare risks include pancreatitis and potential thyroid C‑cell tumors in rodents (contraindicated in MEN2/MTC). Other prescription options if you don’t meet GLP‑1 criteria: phentermine/topiramate (Qsymia), bupropion/naltrexone (Contrave), orlistat; devices like Plenity (for BMI 25–40) and intensive lifestyle programs (e.g., commercial programs or medically supervised programs). Brands and services you can consider Wegovy (semaglutide 2.4 mg) — FDA‑approved for weight management. Zepbound (tirzepatide) — FDA‑approved for weight management and often shows larger average weight loss in trials. Ozempic (semaglutide for diabetes) — sometimes used off‑label for weight loss but different dosing/label. Find a specialist: American Board of Obesity Medicine (ABOM) “Find a Specialist” tool — good way to locate a clinician experienced with these meds. Cost help/price checks: GoodRx can help compare cash prices and coupons. Behavioral support: programs like Noom or referral to a registered dietitian can be useful complements. If you want, give me your height and current weight and I’ll calculate your BMI and tell you whether you currently meet the usual criteria.

Mentioned in position 2 of 5